INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc. - RCKT

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Rocket Pharmaceuticals and its officers or directors [1] Group 1: Company Developments - On May 27, 2025, Rocket Pharmaceuticals announced an update regarding its investigational gene therapy RP-A501 for Danon disease, revealing that a patient in the Phase 2 trial experienced a Serious Adverse Event (SAE) related to capillary leak syndrome [3] - Following the SAE, Rocket paused further dosing in the study, and the FDA placed a clinical hold on the trial for further evaluation [3] - The patient involved in the SAE subsequently passed away due to an acute systemic infection [3] - As a result of this news, Rocket's stock price dropped by $3.94 per share, or 62.84%, closing at $2.33 per share on May 27, 2025 [3] Group 2: Legal and Investigative Actions - Pomerantz LLP is reaching out to investors of Rocket Pharmaceuticals to investigate claims of potential securities fraud [1] - The firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4]